LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mereo BioPharma Group plc, (“Mereo” or the "Company") (NASDAQ: MREO) investors of a class action on behalf of investors that bought securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). Mereo investors have until April 6, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

Core Viewpoint - Mereo BioPharma Group plc is facing a securities class action lawsuit due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [1][1]. Group 1: Legal Action and Deadlines - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The lawsuit alleges that Mereo and its executives made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs [1][1]. Group 2: Clinical Trial Results - Mereo announced on December 29, 2025, that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [1][1]. - Despite showing statistically significant improvements in bone mineral density on secondary endpoints, the failure to meet primary endpoints led to a negative market reaction [1]. Group 3: Stock Price Impact - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, representing an 87.64% decline, closing at $0.28 per share on December 29, 2025 [1][1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements and concealed material adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints [2][3] Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies, claiming confidence in setrusumab's ability to reduce annualized fracture rates [2] - It is claimed that while making these positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 studies, which ultimately did not achieve their primary endpoints [2] - The studies failed to show a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate control groups, leading to artificially inflated prices for Mereo's American Depository Shares (ADS) [2] Group 2: Impact of the Announcement - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies met their primary endpoint, resulting in a significant decline in the price of Mereo's ADS from $2.31 to $0.29, a drop of over 87.7% [3] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Clinical Trial Results - Mereo BioPharma announced on December 29, 2025, that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the failure to meet primary endpoints, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, or 87.64%, closing at $0.28 per share [6]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members [7]. - Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi, LLP is also encouraging anyone with information regarding Mereo BioPharma's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors are encouraged to join the class action, which allows for potential compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased Mereo American Depositary Shares during the specified Class Period, alleging misleading information regarding clinical study results [1][3]. Company Overview - Mereo BioPharma Group plc is a biopharmaceutical company headquartered in London, focusing on treatments for rare diseases [2]. Legal Action Details - The lawsuit claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies for setrusumab, which did not significantly reduce clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Investor Information - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to seek appointment as a lead plaintiff representative of the class [2].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for alleged violations of securities laws, specifically related to misleading statements about its clinical programs [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from June 5, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which did not meet their endpoints compared to placebo or bisphosphonate control groups [2]. Group 2: Investor Participation - Shareholders who purchased MREO shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc for alleged violations of federal securities laws related to misleading statements about its clinical programs [4]. Group 1: Legal Investigation - The law firm is encouraging Mereo investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Mereo, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Mereo and its executives made false statements and failed to disclose the true state of the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [4]. Group 2: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational reach [3]. Group 3: Whistleblower Encouragement - The firm is also seeking information from whistleblowers, former employees, shareholders, and others regarding Mereo BioPharma's conduct [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma Group made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo BioPharma Group securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. The deadline to serve as lead plaintiff is April 6, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].